Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's LymphomaUlrich Mey, Ingo G.H. Schmidt‐Wolf, Ulrich Kaiser et al.|Cancer Investigation|2006Cited by 61
Increase of In Vivo Antitumoral Activity by CD40L (CD154) Gene Transfer Into Pancreatic Tumor Cell-Dendritic Cell HybridsCarsten Ziske, Ingo G.H. Schmidt‐Wolf, Elisabeth Sievers et al.|Pancreas|2009Cited by 13
Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin LymphomaNadine G. D. Schirmbeck, Ingo G.H. Schmidt‐Wolf, Ulrich Mey et al.|Cancer Investigation|2016Cited by 10
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)Frank Griesinger, Dimitri Flieger, Wilfried Eberhardt et al.|JTO Clinical and Research Reports|2023Cited by 4
A Phase II Trial of Dexamethasone, High-Dose Cytarabine, and Cisplatin (DHAP) in Combination with Rituximab as Salvage Treatment for Patients with Refractory or Relapsed Aggressive Non-Hodgkin’s Lymphoma.Ulrich Mey, Ingo G.H. Schmidt‐Wolf, John Strehl et al.|Blood|2004Cited by 3